Olaparib Shows Promise in Treating Cancers Caused by BRCA Mutations

Strategic Insights -

Recent research published in the New U.K. Journal of Medicine has revealed the potential of olaparib, a novel PARP inhibitor, in treating cancers caused by BRCA1 or BRCA2 mutations. The clinical evaluation conducted on 60 patients, including 22 carriers of BRCA1 or BRCA2 mutations, showed that olaparib inhibited PARP and demonstrated antitumor activity in mutation carriers. The study also reported fewer adverse effects compared to conventional chemotherapy. The findings suggest that olaparib could be a promising therapeutic strategy for treating cancers with specific DNA-repair defects.

Key Takeaways:

  • The study involved 60 patients, including 22 carriers of BRCA1 or BRCA2 mutations, and 1 patient with a strong family history of BRCA-associated cancer.
  • The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 weeks to 600 mg twice daily continuously.
  • Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily and two of five patients receiving 600 mg twice daily.
  • The study reported antitumor activity only in mutation carriers, who had ovarian, breast, or prostate cancer and had received multiple treatment regimens.
  • The researchers concluded that olaparib has few adverse effects, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation.
  • The study highlights the potential of olaparib as a therapeutic strategy for treating cancers with specific DNA-repair defects.

Statistics:

  • 22 patients were carriers of BRCA1 or BRCA2 mutations.
  • 1 patient had a strong family history of BRCA-associated cancer but declined to undergo mutational testing.
  • The study enrolled a total of 60 patients.
  • The olaparib dose was increased from 10 mg daily to 600 mg twice daily.
  • 8 patients experienced reversible dose-limiting toxicity at 400 mg twice daily.
  • 5 patients experienced reversible dose-limiting toxicity at 600 mg twice daily.

Sources:

  • "Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. New U.K. Journal of Medicine, 2009;361(2):123-134."
  • ClinicalTrials.gov number, NCT00516373.